Further support for rituximab in relapsing multiple sclerosis
- PMID: 35841895
- DOI: 10.1016/S1474-4422(21)00180-0
Further support for rituximab in relapsing multiple sclerosis
Conflict of interest statement
RTN has consulted for Abata Therapeutics, Banner Life Sciences, BeiGene, Biogen, Bristol Myers Squibb, Genentech, Genzyme, Janssen, GW Therapeutics, Horizon Therapeutics, Lundbeck, NervGen, TG Therapeutics. AHC has received consultant fees from Biogen, Bristol Myers Squibb, EMD Serono Research & Development Institute, an affiliate of Merck, Genentech, Horizon, Janssen (J&J), Jazz Pharmaceuticals, Novartis, and TG Therapeutics; has been supported for travel to meetings by Novartis, Horizon, and EMD Serono (Merck); has a patent for methods for simultaneous multi-angular relaxometry of tissue using MRI; and is on Scientific advisory boards for EMD Serono, Genentech, Novartis, the Consortium of MS Centers, and the National MS Society USA.
Comment on
-
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial.Lancet Neurol. 2022 Aug;21(8):693-703. doi: 10.1016/S1474-4422(22)00209-5. Lancet Neurol. 2022. PMID: 35841908 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical